Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Clinical implication of Retinitis Pigmentosa molecular diagnostic using high throughput sequencing (RP-SEQ-HD)

In this page

Clinical Trial

NCT02860520 Recruiting, Active
Clinical implication of Retinitis Pigmentosa molecular diagnostic using high throughput sequencing (RP-SEQ-HD)

Clinical implication of Retinitis Pigmentosa molecular diagnostic using high throughput sequencing (RP-SEQ-HD).

Observational
Observational

Disease

Disease type

Retinitis Pigmentosa

Orphan drug recognition

NA

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

01/09/2015

Closing date

30/09/2018

Inclusion criteria :

More

Exclusion criteria :

More

Funding

national institution

Members involved

Main investigators

Pr Hélène Dollfus

Representative

France

Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Epag, ERN-EYE Coordinating committee, Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Others investigators

ERN EYE member investigating site

HCP : Principal investigators

CARGO, Hôpitaux Universitaires de Strasbourg, France

Adress

Hôpital Civil -Bâtiment du Centre de Recherche en Biomédecine de Strasbourg (CRBS),1 Rue Eugène Boeckel

67000 STRASBOURG

France